Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.38 |
| ▸ | BMP1 | P13497 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257359 | 0.87 | MAPT (0.43) | PTGER1MMP9MMP1MMP13KEAP1 | |
| SCHEMBL5982918 | 0.86 | POLB (0.44) | PTGER1MMP9MMP1MMP13KEAP1 | |
| SCHEMBL2581362 | 0.79 | KEAP1 (0.47) | KEAP1NFE2L2BMP1MCL1 | |
| SCHEMBL5026438 | 0.79 | PTGER1 (0.38) | PTGER1MMP9MMP1MMP13KEAP1 | |
| SCHEMBL8370091 | 0.77 | KEAP1 (0.45) | KEAP1NFE2L2MEN1KMT2AMCL1 | |
| SCHEMBL7257038 | 0.75 | KEAP1 (0.48) | MMP9MMP1MMP13KEAP1NFE2L2 | |
| SCHEMBL7452491 | 0.75 | KEAP1 (0.50) | MMP9MMP1MMP13KEAP1NFE2L2 | |
| SCHEMBL7447488 | 0.74 | CYP2C9 (0.43) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6395395 | 0.73 | KEAP1 (0.36) | PTGER1MMP9MMP1MMP13KEAP1 | |
| SCHEMBL5981554 | 0.71 | MCL1 (0.39) | MEN1KMT2AMAPTMCL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | PTGER1 3354/4885MMP9 782/4885MMP1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.